Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
95 hedge funds and large institutions have $396M invested in Albireo Pharma Inc in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 40 increasing their positions, 31 reducing their positions, and 19 closing their positions.
34% more call options, than puts
Call options by funds: $1.25M | Put options by funds: $931K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
29% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 31
6% more capital invested
Capital invested by funds: $372M → $396M (+$23.8M)
12% less funds holding
Funds holding: 108 → 95 (-13)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$12.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.65M |
| 3 |
CC
Chicago Capital
Chicago,
Illinois
|
+$5.13M |
| 4 |
BlackRock
New York
|
+$2.74M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$14.5M |
| 2 |
PA
Perceptive Advisors
New York
|
-$12.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$6.37M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.23M |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$2.99M |
ALBO Hedge Fund Activity: Q4 2022 in Review
95 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2022, worth a combined $396M — up 6.4% from $372M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ALBO and 8 opened new positions — a net loss of 11 holders — while 31 trimmed existing stakes and 40 added.
The largest buyer was Deep Track Capital, adding an estimated $12.5M. The largest seller was Tang Capital Management, cutting an estimated $14.5M.
- 95 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2022, down from 108 in Q3 2022.
- Funds reported $396M of Albireo Pharma Inc stock for Q4 2022, up 6.4% quarter-over-quarter.
- 8 funds opened new Albireo Pharma Inc positions in Q4 2022 and 19 closed out, a net change of -11 holders.
- The largest Albireo Pharma Inc buyer in Q4 2022 was Deep Track Capital, an estimated $12.5M added.
- The largest Albireo Pharma Inc seller in Q4 2022 was Tang Capital Management, an estimated $14.5M sold.
Based on aggregated 13F filings for Q4 2022.